Catriona Yale
CIK 1779308 · Chief Development Officer · last filed 2025-12-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
52
Lifetime Open-Market Net
-$17.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) Delisted | Chief Development Officer | 0 | $54.65 | $0 | -$17.93M | 52 | 2025-12-09 |
Recent Filings · Page 5 of 6
52 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-11-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −5,000 | -$197.1K | EDGAR |
| 2022-10-12 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −5,000 | -$189.9K | EDGAR |
| 2022-09-15 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −40,000 | -$1.10M | EDGAR |
| 2022-09-13 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +1,152 | $9.3K | EDGAR |
| 2021-12-10 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-18 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −12,500 | -$269.8K | EDGAR |
| 2021-09-17 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −12,500 | -$308.6K | EDGAR |
| 2021-08-17 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −10,000 | -$187.9K | EDGAR |
| 2021-07-19 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −10,000 | -$209.0K | EDGAR |
| 2020-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +1,245 | $21.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.